CAP 2026

Pathology Reimagined explores how digital and computational technologies are transforming pathology while strengthening the pathologist’s central role. As the field evolves from a glass slide-based discipline to a digitally connected, data-driven specialty, leaders from the Digital Pathology Association will examine the technologies, strategies, and real-world implementations driving this change.

The session will address the digital foundations needed for modern pathology, including infrastructure, workflows, and organizational strategies. It will then explore how computational tools and pathologist-led biomarker testing are advancing precision medicine and personalized care. Finally, attendees will examine intelligent pathology and how digital pathology and artificial intelligence can reduce repetitive work, address workforce challenges, and enable pathologists to focus their expertise where it matters most.

Together, these perspectives offer a practical vision for pathology’s future—where technology and human expertise work in partnership to improve quality, access, innovation, and patient care.

Speakers

Matthew Hanna, MD
Vice Chair of Pathology Informatics
UPMC

Matthew G Hanna, MD is the Vice Chair of Pathology Informatics at the University of Pittsburgh Medical Center (UPMC). Dr Hanna serves on the UPMC Computational Pathology & AI Center of Excellence (CPACE) Senior Director of AI Operations. He is an internationally recognized leader in digital and computational pathology, with a focus on translating digital operations and artificial intelligence into routine clinical practice. Dr. Hanna serves on the Executive Board of the Digital Pathology Association. He also actively contributes as a member of the CAP as the Chair of the Artificial Intelligence Committee and member of the Council of Informatics and Pathology Innovation. His clinical interests include breast pathology, informatics, digital pathology, image analysis, machine learning, clinical operations/implementation, and decision support tools.

DPA Highlight & Building the Digital Foundation

Digital pathology is no longer an emerging technology. It is rapidly becoming the foundation upon which computational pathology, artificial intelligence, precision diagnostics, and enterprise-imaging are being built. Yet many organizations remain challenged by the practical realities of moving from pilot projects to sustainable, scalable digital operations.

This session will explore the essential building blocks of successful digital pathology programs, from whole slide imaging and enterprise infrastructure to workflow redesign, governance, interoperability, and clinical adoption. Drawing from large-scale implementation experiences, attendees will learn how digital pathology serves as the platform that enables computational innovation while delivering immediate operational value through improved collaboration, subspecialty access, standardization, education, and quality.

The presentation will highlight key lessons learned from organizations that have successfully transitioned from glass-based workflows to fully digital ecosystems and discuss how these investments create the foundation for future advances in artificial intelligence, biomarker quantification, precision medicine, and integrated diagnostics. Participants will leave with a practical framework for understanding where digital pathology creates value today and why it represents a strategic imperative for the future of pathology practice.

Marilyn M. Bui, MD, PhD
Pathologist, Professor, and Lab Director
Moffitt Cancer Center

Marilyn M. Bui, MD, PhD, FCAP, is a board-certified anatomic, clinical, and cytopathologist and a tenured Senior Member of the Departments of Pathology, Machine Learning, and Translational Pathology at Moffitt Cancer Center & Research Institute in Tampa, Florida. She is a Professor at the University of South Florida Morsani College of Medicine. She serves as Scientific Director of the Analytic Microscopy Core, Section Head of Bone and Soft Tissue Pathology, and Chair of the Women in Oncology Executive Board. She previously directed the Cytopathology Fellowship Program for 14 years.

Dr. Bui earned her medical degree in Beijing, China, and her PhD in Molecular Pathology and Immunology from the University of Florida, where she completed residency in anatomic and clinical pathology as chief resident and a fellowship in cytopathology. Her clinical and research expertise includes bone and soft tissue pathology, cytopathology, biomarker testing, digital pathology, artificial intelligence, and precision medicine. She has served as co-investigator and study pathologist on numerous research grants and has authored 247 peer-reviewed publications with more than 10,000 citations, 33 book chapters, and three books. She serves on multiple journal editorial boards, holds three patents in digital pathology and cancer diagnostics, and has received numerous honors, including the 2019 College of American Pathologists (CAP) Distinguished Patient Care Award. Dr. Bui is a nationally and internationally recognized pathology leader. She is a past president of the Digital Pathology Association (DPA), Chinese American Pathologists Association, Florida Society of Pathologists (FSP), and Moffitt Medical Staff, and served for 14 years on the NCCN Soft Tissue Sarcoma Guidelines Panel. A CAP member for more than 20 years, she has chaired major CAP committees, including Publications, CAP Today Editorial Board, and Digital and Computational Pathology. She has served two terms as Vice Speaker of the CAP House of Delegates and an ex-officio member of the Board of Governors. Recently, she was elected Speaker of the House of Delegates and will be installed at CAP26. An award-winning educator and mentor, Dr. Bui has led innovative educational initiatives, including the Precision Medicine Academy of FSP and Digital Anatomic Pathology Academy of DPA. She advocates for the essential role of pathology in precision medicine and has been featured in scientific journals, podcasts, media outlets, and documentary film.

Augmented Precision Pathology Through Pathologist-Led Biomarker Testing

Precision medicine is transforming cancer care, and pathology stands at the center of this evolution. As biomarker testing grows in complexity and clinical importance, pathologists are increasingly leveraging digital pathology, computational tools, and augmented intelligence to improve diagnostic accuracy, standardize interpretation, and accelerate access to targeted therapies.

This session explores how pathologist-led innovation is advancing the next generation of precision oncology. Through the lens of biomarker development and clinical implementation, attendees will examine the expanding role of digital pathology and artificial intelligence in supporting quantitative assessment, enhancing diagnostic confidence, and enabling more personalized treatment decisions. The presentation will also highlight the importance of collaboration among pathologists, diagnostic companies, and pharmaceutical partners in translating scientific discoveries into clinically actionable tests.

By integrating human expertise with computational technologies, pathology is becoming an increasingly powerful driver of precision care. Participants will gain a deeper understanding of how digital and computational pathology can augment pathologist performance, improve biomarker testing, and help deliver the right therapy to the right patient at the right time.

Eric F. Glassy, MD, FCAP

Affiliated Pathologists Medical Group, Inc.

Dr. Glassy is a community pathologist in Southern California and co-director of pathology at Providence Little Company of Mary Medical Center, San Pedro. He is a member of Affiliated Pathologists Medical Group, a 40-person independent pathology group covering 15 hospitals and laboratories in California, Portland, and Phoenix. Dr. Glassy has won several pathology awards, including the Distinguished Service Award, Excellence in Education Award, and Pathologist of the Year (2025) from the College of American Pathologists (CAP). He has chaired hospital and CAP national committees, serving as chairman of the Hematology and Clinical Microscopy, Publications, Digital Pathology, Curriculum, and Information Technology Leadership Committees and the Council on Membership and Professional Development.

He is a past Governor of the CAP, the CAP Foundation, and a graduate of the CAP Engaged Leadership Academy. He is past president of the Digital Pathology Association. He edited, wrote, and illustrated five pathology color atlases and developed software programs for pathology reporting, outreach, and practice management. He holds a green belt in Six Sigma. Dr. Glassy is a former trustee of the American Board of Pathology. He received his medical degree from the University of California, San Francisco, and completed his pathology residency and hematopathology fellowship at Harbor-UCLA Medical Center.

Smarter, Not Harder: The Case for Intelligent Pathology

The promise of AI and digital pathology is often framed in terms of throughput — more slides, faster turnaround, greater efficiency. This talk proposes a different measure of success: not how much more pathologists can produce, but how much less time they spend on work that diminishes them.

This presentation will introduce the “Doing Less with More” framework. It will explore how intelligent technology can reduce repetitive, high-volume, and cognitively depleting tasks that dominate pathology workflows, freeing pathologists to focus on complex diagnoses, clinical consultations, and the human judgment at the heart of the specialty.

Drawing on real-world implementation experience in community and academic settings, this session explores how digital pathology platforms and AI-assisted tools are already reshaping daily practice — practical solutions to shared challenges including rising operational costs, workforce shortages, and growing demand for subspecialty expertise in under-resourced settings.

Attendees will leave with a clearer understanding of implementation opportunities and a renewed sense of pathology’s potential when partnering with technology to carry more of the burden.